7 matches for your search in the start-up spotlight
rss
Including cell therapy candidates and related platform technologies
03-Dec-2024
Roche announced that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc., a public clinical-stage biopharmaceutical company pioneering donor-derived CAR-T cell therapies. Based in San Diego, California, Poseida’s R&D portfolio includes pre-clinical and ...
PhoreMost to deploy its SITESEEKER platform to identify novel targets for Roche’s discovery programmes
07-Sep-2022
PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, announced it has entered into a multi-project target discovery collaboration with Roche. Under the terms of the agreement, PhoreMost will receive an upfront payment and is eligible for ...
06-Jun-2022
Repare Therapeutics Inc. announced it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib (also known as RP-3500), a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related ...
24-May-2022
KaliVir Immunotherapeutics, Inc. announced a collaboration and global exclusive licensing agreement with Roche for the discovery, development and commercialization of novel oncolytic vaccinia viruses derived from KaliVir's oncolytic immunotherapy VETTM platform. KaliVir will work with Roche to ...
Start-up combines cutting-edge AI data-driven algorithms, mechanism-driven quantum mechanics and molecular dynamics simulations
23-May-2022
METiS announced officially joining the Roche Accelerator with the goal to tap into Roche’s global scientific expertise, laboratory facilities and foster collaboration discussions on formulation development and optimization with Roche Innovation Center Shanghai. "We are excited to become a member ...
Orally available NLRP3 inflammasome inhibitors to address clinical unmet needs across a wide variety of inflammatory diseases
22-Sep-2020
Inflazome announced that it has closed a share purchase agreement with Roche in which Inflazome’s shareholders received an upfront payment of €380 million, and are eligible to receive additional contingent payments to be made based on the achievement of certain predetermined milestones. ...
09-Oct-2018
GO Therapeutics, Inc. (GO) announced that it has entered into a license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche). Under the terms of the agreement, GO will grant Roche a worldwide, exclusive license for antibodies generated to address a novel cancer-specific ...
